Notable healthcare headlines for the week: Health insurers, Pfizer, and J&J in focus
at seekingalpha.com (Sun, 22-Nov 9:05 AM)
50 Russell 1000 stocks mutual funds avoid most - Goldman
at seekingalpha.com (Fri, 20-Nov 11:59 AM)
Pfizer Advances RSV Booster Study in Older Adults
at www.tipranks.com (Fri, 20-Nov 11:31 AM)
Bipartisan panel says China 'doubling down' on control of pharma supply chain
at seekingalpha.com (Thu, 19-Nov 4:09 PM)
Pfizer Advances Phase 3 Trial of Berobenatide for Women With Incontinence and Excess Weight
at www.tipranks.com (Thu, 19-Nov 11:31 AM)
Pfizer Updates Real-World Migraine Study as Investors Watch Nurtec’s Staying Power
at www.tipranks.com (Thu, 19-Nov 11:30 AM)
AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma
at seekingalpha.com (Thu, 19-Nov 2:30 AM)
Fate of Trump's new FDA commissioner nominee will fall on Senate Democrats
at seekingalpha.com (Wed, 18-Nov 10:22 AM)
Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B
at seekingalpha.com (Wed, 18-Nov 7:16 AM)
Trump abandons Heidi Overton as FDA commissioner nominee: reports
at seekingalpha.com (Tue, 17-Nov 10:17 PM)
Pfizer Updates Real-World Safety Study of Xeljanz XR
at www.tipranks.com (Tue, 17-Nov 11:30 AM)
Leerink Partners Keeps Their Hold Rating on Pfizer (PFE)
at www.tipranks.com (Tue, 17-Nov 1:55 AM)
Options Expect a Bigger Pfizer Move Than It Usually Makes After Earnings
Market Chameleon (Fri, 30-Oct 12:04 PM)